Lilly and the FDA had notified healthcare professionals of changes to the Prescribing Information for Zyprexa (olanzapine) related to its indication for use in adolescents (13–17 years of age) for the treatment of schizophrenia and bipolar I disorder. The revised labeling includes recommendations for considering the possible long-terms risks when prescribing Zyprexa to adolescents due to the increased potential for weight gain and hyperlipidemia. Additionally, there is a recommendation for a comprehensive Treatment Program in Pediatric Patients as part of a total treatment program for pediatric patients with schizophrenia and bipolar disorder that may include other measures (eg, psychological, educational, social) for patients with the disorder.

For more information visit www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198402.htm.